Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
Background:
- Sunitinib is drug that is approved for treating various types of cancers, including kidney
cancers. However, it has not been approved to treat cancers of the thymus. Sunitinib works by
blocking proteins that are responsible for cell division and growth. Some of these proteins
can be found on thymus cancer cells. Researchers want to see if sunitinib can be used to
treat advanced thymus cancer. It will be given to people who have had at least one earlier
chemotherapy treatment containing platinum.
Objectives:
- To see if sunitinib is a safe and effective treatment for advanced thymus cancer that has
not responded to earlier treatments.
Eligibility:
- Individuals at least 18 years of age who have advanced thymus cancer that has not
responded to earlier treatments.
- At least one previous cancer treatment must have been chemotherapy treatment containing
platinum.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies and tumor biopsies will be used to check the
severity of the cancer.
- Participants will take sunitinib tablets once a day, in the morning. They will take the
tablets daily for 4 weeks, followed by 2 weeks of rest with no sunitinib. This 6-week
period is called a cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Treatment cycles may be repeated as long as the tumor does not continue to grow and
there are no severe side effects....
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborators:
Indiana University School of Medicine Indiana University Simon Cancer Center